Abstract:The (18 kDa) Translocator Protein (TSPO), was initially identified in 1977 as peripheral binding site for the benzodiazepine diazepam and named "Peripheral-type benzodiazepine receptor (PBR)". It is an evolutionarily well-conserved protein particularly located at the outer/inner mitochondrial membrane contact sites, in closely association with the 32 kDa voltage-dependent anion channel (VDAC) and the 30 kDa adenine nucleotide translocase (ANT), thus forming the mitochondrial permeability transition pore (MPTP). TSPO is ubiquitary expressed in peripheral tissues (steroid producing tissues, liver, heart, kidney, lung, immune system) and in lower levels in the central nervous system, where it is mainly located in glial cells, and in neurons. TSPO is involved in a variety of biological processes such as cholesterol transport, steroidogenesis, calcium homeostasis, lipid metabolism, mitochondrial oxidation, cell growth and differentiation, apoptosis induction, and regulation of immune functions. In the last decade, many studies have reported that TSPO basal expression is altered in a number of human pathologies, such as cancer and neurodegenerative disorders (Huntington's and Alzheimer's diseases), as well as in various forms of brain injury and inflammation and anxiety. Consequently, TSPO has not only been suggested as a promising drug target for a number of therapeutic applications (anticonvulsant, anxiolytic, immunomodulating, etc.), but also as valid diagnostic marker for related-disease state and progression, prompting the development of specific labelled ligands as powerful tools for imaging techniques. A number of structurally different classes of ligands have been reported, showing high affinity and selectivity towards TSPO. Indeed, most of these ligands have been designed starting from selective CBR ligands which were structurally modified in order to shift their affinity towards TSPO. Extensive structure-activity relationship studies were performed allowing to hypothesize various TSPO pharmacophore models. The purpose of this paper is to highlight the structural requirements needed to obtain TSPO ligands with high affinity and selectivity.

Current advances in the structure–activity relationship (SAR) analysis of the old/new 18-kDa translocator protein ligands

Structural Requirements to Obtain Highly Potent and Selective 18 kDa Translocator Protein (TSPO) Ligands

Structure-Based Drug Design for TSPO: Challenges and Opportunities

Translocator Protein (18 Kda): A Promising Therapeutic Target and Diagnostic Tool for Cardiovascular Diseases

Recent developments on PET radiotracers for TSPO and their applications in neuroimaging

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update

Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases

Recent progress on the development of fluorescent probes targeting the translocator protein 18 kDa (TSPO)

The mitochondrial translocator protein (TSPO) in Alzheimer's disease: Therapeutic and immunomodulatory functions

TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward

Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases

Emerging TSPO-PET Radiotracers for Imaging Neuroinflammation: A Critical Analysis

Potential of TSPO Radioligands: Bridging Brain Tumor Diagnostics to the Peripheries

New Structure–activity Relationships of N-acetamide Substituted Pyrazolopyrimidines As Pharmacological Ligands of TSPO

Roles of TSPO and Its Ligands in Different Neurologic Diseases

Functional role of translocator protein and its ligands in ocular diseases (Review)

Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa)

Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening.

Design, synthesis, characterization and evaluation of methionine-ABO based TSPO ligand

Synthesis and pharmacological evaluation of [18F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971